IL324979A - מעכבי פרנזילטרנספראז לטיפול בסרטן התלוי ב-kras - Google Patents
מעכבי פרנזילטרנספראז לטיפול בסרטן התלוי ב-krasInfo
- Publication number
- IL324979A IL324979A IL324979A IL32497925A IL324979A IL 324979 A IL324979 A IL 324979A IL 324979 A IL324979 A IL 324979A IL 32497925 A IL32497925 A IL 32497925A IL 324979 A IL324979 A IL 324979A
- Authority
- IL
- Israel
- Prior art keywords
- kras
- cancer
- inhibitor
- compound
- adagrasib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363505272P | 2023-05-31 | 2023-05-31 | |
| US202363580680P | 2023-09-05 | 2023-09-05 | |
| US202463556282P | 2024-02-21 | 2024-02-21 | |
| US202463639307P | 2024-04-26 | 2024-04-26 | |
| PCT/US2024/031545 WO2024249551A1 (en) | 2023-05-31 | 2024-05-30 | Farnesyltransferase inhibitors for treatment of kras-dependent cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL324979A true IL324979A (he) | 2026-01-01 |
Family
ID=91738687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL324979A IL324979A (he) | 2023-05-31 | 2024-05-30 | מעכבי פרנזילטרנספראז לטיפול בסרטן התלוי ב-kras |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4719410A1 (he) |
| JP (1) | JP2026520480A (he) |
| KR (1) | KR20260018865A (he) |
| CN (1) | CN121311227A (he) |
| AU (1) | AU2024280704A1 (he) |
| IL (1) | IL324979A (he) |
| WO (1) | WO2024249551A1 (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4596552A1 (en) | 2022-09-29 | 2025-08-06 | Guangzhou Joyo Pharmatech Co., Ltd | Macrocyclic derivative and use thereof |
| WO2026117554A1 (en) | 2024-11-26 | 2026-06-04 | Kura Oncology, Inc. | Methods of preparing macrocyclic compounds and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4426303B1 (en) * | 2021-11-02 | 2025-10-08 | Semmelweis Egyetem | Farnesyl-transferase inhibitors and kras inhibitors for treating kras mutant cancers |
| IL312132A (he) | 2021-11-30 | 2024-06-01 | Kura Oncology Inc | מרכיבים מקרוציקליים המציגים פעילות מעכבת של פרנזילטרנספרזי |
| WO2023209073A1 (en) * | 2022-04-28 | 2023-11-02 | Institut National de la Santé et de la Recherche Médicale | Combination of ras inhibitors and farnesyltransferase inhibitors for the treatment of cancers |
-
2024
- 2024-05-30 IL IL324979A patent/IL324979A/he unknown
- 2024-05-30 AU AU2024280704A patent/AU2024280704A1/en active Pending
- 2024-05-30 WO PCT/US2024/031545 patent/WO2024249551A1/en not_active Ceased
- 2024-05-30 EP EP24737193.3A patent/EP4719410A1/en active Pending
- 2024-05-30 KR KR1020257042379A patent/KR20260018865A/ko active Pending
- 2024-05-30 CN CN202480039159.6A patent/CN121311227A/zh active Pending
- 2024-05-30 JP JP2025569652A patent/JP2026520480A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024280704A1 (en) | 2026-01-08 |
| KR20260018865A (ko) | 2026-02-09 |
| JP2026520480A (ja) | 2026-06-23 |
| EP4719410A1 (en) | 2026-04-08 |
| WO2024249551A1 (en) | 2024-12-05 |
| CN121311227A (zh) | 2026-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nagelkerke et al. | Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy | |
| Linch et al. | Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies | |
| CN113382731A (zh) | 包含tno155和瑞博西尼的药物组合 | |
| EP4719410A1 (en) | Farnesyltransferase inhibitors for treatment of kras-dependent cancers | |
| WO2018156812A1 (en) | Treatment of egfr-driven cancer with fewer side effects | |
| AU2015209133B2 (en) | Apilimod compositions and methods for using same | |
| AU2016297555B2 (en) | Methods for treating cancer using apilimod | |
| TWI685341B (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| TW201639578A (zh) | 阿吡莫德之活性代謝物及其用途 | |
| US20120276093A1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an anti-neoplastic agent | |
| CN110996960A (zh) | 第三代egfr酪氨酸激酶抑制剂和raf抑制剂的治疗组合 | |
| Khokhar et al. | Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies | |
| AU2018360559A1 (en) | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use | |
| Castellanos et al. | Generations of epidermal growth factor receptor tyrosine kinase inhibitors: perils and progress | |
| KR20230008719A (ko) | Tno155 및 나자르티닙을 포함하는 약제학적 조합물 | |
| CN116723858A (zh) | 图卡替尼联合曲妥珠单抗、紫杉烷和vegfr-2拮抗剂治疗her2阳性癌症的方法 | |
| JP7468829B2 (ja) | 癌を処置するための、癌治療剤と組み合わせたＩＲＥ１α阻害剤 | |
| US20260115189A1 (en) | Combination Treatment Regimens - SMARCA2 Degrader With Taxane Anticancer Agent | |
| WO2015153866A1 (en) | Cancer therapy with ganetespib and an egfr inhibitor | |
| EP2928488A1 (en) | Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder | |
| US11911374B2 (en) | Methods and uses for treating cancer | |
| Einhorn et al. | Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer | |
| Wagner | Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs | |
| HK40060474A (en) | Pharmaceutical combination comprising tno155 and ribociclib | |
| WO2019183385A1 (en) | Mapk/erk inhibition for ovarian and other cancers |